Potential of albumin dialysis at terminal liver failure in patients with chronic liver diseases by O. E. Nikiforova, Ye. N. Bessonova, O. M. Lesnyak, O. A. Stroganova

“…In relation to etiology of disease all patients were divided into three groups: 1) cirrhoses of the nontoxic etiology as an outcome of viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis; 2) cirrhosis of toxic (alcohol-induced) etiology and 3) focal liver lesions – hepatocellular carcinoma (HCC).Results. …”
Get full text

Hyperthyroidism with Biventricular Heart Failure and Cirrhotic Transformation of the Liver by Rashmi Dhital, Shivani Vyas, Priyadarshani Sharma, Theresa Lynn, Oreoluwa Oladiran, Sijan Basnet

“…Ultrasound of the abdomen was suggestive of liver cirrhosis and ascites, which was thought to be cardiac cirrhosis, after multiple negative work-ups for alternate causes of cirrhosis. …”
Get full text

L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle by Roger F. Butterworth

“…Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health-related quality of life (HRQOL), and patient survival. …”
Get full text

CD300E+ macrophages facilitate liver regeneration after splenectomy in decompensated cirrhotic patients by Tao Yang, Yuan Zhang, Chujun Duan, Hui Liu, Dong Wang, Qingshan Liang, Xiao Chen, Jingchang Ma, Kun Cheng, Yong Chen, Ran Zhuang, Jikai Yin

“…Abstract Liver cirrhosis is prognostically associated with poor life expectancy owing to subsequent liver failure. …”
Get full text

Medical Management of Chronic Cholestatic Liver Diseases by Andrea A Gossard, Keith D Lindor

“…Primary biliary cirrhosis and primary sclerosing cholangitis are reviewed in detail, and management options are identified. …”
Get full text

Clinical Features and Outcomes of Repeated Endoscopic Therapy for Esophagogastric Variceal Hemorrhage in Cirrhotic Patients: Ten-Year Real-World Analysis by Jia-li Ma, Ling-ling He, Ping Li, Yu Jiang, Ju-long Hu, Yu-ling Zhou, Xiu-xia Liang, Hong-shan Wei

“…The median survival time was significantly longer in viral cirrhosis patients (47.1 months [95% CI: 24.9-69.1]) compared with nonviral cirrhosis patients (37.0 months [95% CI: 25.0-56.0], p=0.001). …”
Get full text

Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations by Sherif Elhosseiny, Hassan Al Moussawi, Jean M. Chalhoub, James Lafferty, Liliane Deeb

“…Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. …”
Get full text

Diagnostic Value of the 13C Methacetin Breath Test in Various Stages of Chronic Liver Disease by Hamizah Razlan, Nurhayaty Muhamad Marzuki, Mei-Ling Sharon Tai, Azhar-Shah Shamsul, Tze-Zen Ong, Sanjiv Mahadeva

“…Area under curve values for fibrosis was 0.62 (0.39–0.86), whilst that for cirrhosis (all stages) was 0.95 (0.91–0.99). The 13C-methacetin breath test has a poor predictive value for liver fibrosis but accurately determines advanced cirrhosis.…”
Get full text

The Relationship between Inflammatory Marker Levels and Hepatitis C Virus Severity by Qitian He, Quan He, Xue Qin, Shan Li, Taijie Li, Li Xie, Yan Deng, Yu He, Yongbin Chen, Zhifu Wei

“…The areas under the curve of the RDW, RPR, and 1/PLR for predicting cirrhosis were 0.791, 0.960, and 0.713, respectively. …”
Get full text

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study by Seyed Moayed Alavian, Mohammad Tasavon Gholamhoseini, Heidar Sharafi, Helena HL Borba, Asma Sabermahani, Behzad Hajarizadeh

“…Among generic pan-genotypic DAA regimens, SOF/VEL was cost-effective, for people with no cirrhosis and cost-saving for those with cirrhosis.…”
Get full text

Prevention and Management of Variceal Hemorrhage by Dong Hyun Kim, Jun Yong Park

“…Variceal hemorrhage is a common and devastating complication of portal hypertension and is a leading cause of death in patients with cirrhosis. The management of gastroesophageal varices has evolved over the last decade resulting in improved mortality and morbidity rates. …”
Get full text

Treatment of Decompensated Alcoholic Liver Disease by John Menachery, Ajay Duseja

“…Alcoholic liver disease (ALD) is a spectrum ranging from simple hepatic steatosis to alcoholic hepatitis and cirrhosis. Patients with severe alcoholic hepatitis can have clinical presentation almost similar to those with decompensated cirrhosis. …”
Get full text

The Role of Correcting Structural and Functional Albumin Properties in Ascites Control in Decompensated Cirrhotic Patients by A. A. Turkina, M. V. Maevskaya, M. S. Zharkova, V. T. Ivashkin

“…Fifty patients with decompensated liver cirrhosis and ascites were divided into groups. The first group received standard treatment for cirrhosis, the second — standard treatment and replacement therapy with 20 % human albumin solution at a dose of 200 mL per week for 3 months.Results. …”
Get full text

Liver Transplantation and Hepatitis C by Nobuhisa Akamatsu, Yasuhiko Sugawara

“…Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. …”
Get full text

Management of Diabetes Mellitus in Patients with Chronic Liver Diseases by Yingying Zhao, Huichun Xing, Xiaomei Wang, Weini Ou, Hong Zhao, Ben Li, Yue Li, Ying Duan, Liwei Zhuang, Wei Li, Danying Cheng, Min Quan, Yu Zhang, Shibo Ji

“…Liver cirrhosis and diabetes influence each other. Thus, in addition to pharmacological treatments and lifestyle interventions, effective control of cirrhosis might assist in a better management of diabetes. …”
Get full text

Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study by Qi Fan, MM, Pengcheng Wei, MM, Delin Ma, MD, Qian Cheng, MD, Jie Gao, MD, Jiye Zhu, MD, Zhao Li, MD

Get full text

The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease by James P. Hardwick, Byoung-Joon Song, Paul Rote, Charles Leahy, Yoon Kwang Lee, Alexandra Rudi Wolf, Danielle Diegisser, Victor Garcia

“…IntroductionMetabolic-dysfunction-associated steatosis liver disease (MASLD) is a progressive liver disease from simple steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Chronic liver diseases (CLDs) can lead to portal hypertension, which is a major cause of complications of cirrhosis. …”
Get full text

Taba Binary, Multinomial, and Ordinal Regression Models: New Machine Learning Methods for Classification by Mohammad Tabatabai, Derek Wilus, Chau-Kuang Chen, Karan P. Singh, Tim L. Wallace

“…To evaluate the performance of Taba regression, liver cirrhosis data obtained from a Mayo Clinic study were analyzed. …”
Get full text

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence by Zhaohui Bai, Yang An, Xiaozhong Guo, Rolf Teschke, Nahum Méndez-Sánchez, Hongyu Li, Xingshun Qi

“…Terlipressin has not been considered as the mainstay treatment option for ascites in cirrhosis yet. The present work aimed to systematically review the current evidence regarding the use of terlipressin in cirrhosis with ascites and without hepatorenal syndrome. …”
Get full text

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

“…The drug possesses favorable safety profile, including at treatment of liver cirrhosis.…”
Get full text